Press Releases

    • FEB 10 2015

    Oncoceutics to Present at the Leerink Global Healthcare Conference

    Hummelstown, PA (February 9, 2015) – Oncoceutics, Inc., a drug discovery and development company targeting the most potent suppressor pathways in human cancer, announced today that Wolfgang Oster, M.D., Ph.D., Chief Executive Officer, will present a corporate overview at the 2015 Leerink Global Healthcare Conference on Thursday, February 12, 2015, at 1:25 pm ET, at

    • JAN 06 2015

    Novel anti-cancer drug, ONC201, focus of alliance between Oncoceutics and MD Anderson Cancer Center

    Hummelstown, PA (January 5, 2015) – Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug. Earlier preclinical studies of ONC201 have indicated there is merit in further investigation of the drug,

    • DEC 09 2014

    Multiple Abstracts Selected for 2014 ASH Annual Meeting Demonstrating Safety and Efficacy of Oncoceutics’ ONC201

    Hummelstown, PA (December 8, 2014) – Oncoceutics, Inc. announced that seven multi-investigator abstracts were selected for the 2014 annual meeting of the American Society of Hematology (ASH) that is being held December 6-9 in San Francisco, CA. Taken together, these abstracts ubiquitously describe compelling efficacy and safety of ONC201 in pre-clinical settings across the spectrum

    • NOV 21 2014

    Oncoceutics Initiates Collaborations with Fox Chase Cancer Center

    Hummelstown, PA (November 7, 2014) – Oncoceutics, Inc., announces the initiation of multifaceted preclinical collaborations with Fox Chase Cancer Center on its lead compound ONC201. These programs are supported in part by an NIH RO1 grant to study the mechanism of action of the first-in-class ONC201 anti-cancer drug candidate that was awarded to Wafik El-Deiry,